Sort by
Previous Page Page 1 of 2 Next Page
  1. Review

    The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy

    Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a very high economic impact. Peginterferon beta-1a is the first approved pegylated interferon beta-1a for the treatm...

    Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani and Pier Luigi Canonico

    Multiple Sclerosis and Demyelinating Disorders 2017 2:13

    Published on: 21 August 2017

  2. Short report

    Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis

    To assess the association between objective bladder function parameters in relation to urinary symptoms, and to analyze the sensitivity and specificity of subjective urinary symptom-assessment in predicting ob...

    Shalom Haggiag, Giovanni Bolla, Orietta Picconi, Simonetta Galgani and Claudio Gasperini

    Multiple Sclerosis and Demyelinating Disorders 2017 2:11

    Published on: 7 August 2017

  3. Research article

    Cardiovascular comorbidity in multiple sclerosis patients treated with Mitoxantrone therapy: a cohort study

    Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS). Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered ...

    Paolo Ragonese, Paolo Aridon, Sabrina Realmuto, Giulia Vazzoler, Simona Alessi, Erika Portera, Alessia Bianchi, Fabio Triolo, Maria Antonietta Mazzola, Marco D’Amelio, Giovanni Savettieri and Giuseppe Salemi

    Multiple Sclerosis and Demyelinating Disorders 2017 2:12

    Published on: 24 July 2017

  4. Research article

    Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis

    Fingolimod is an efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) and there is class I evidence that it is superior to standard care in reducing relapse rate. However, real-world data in...

    Manuela Giuliani, Alessandra Logoteta, Luca Prosperini, Maria Neve Hirsch and Carlo Pozzilli

    Multiple Sclerosis and Demyelinating Disorders 2017 2:10

    Published on: 26 June 2017

  5. Review

    Alemtuzumab for multiple sclerosis: the new concept of immunomodulation

    Alemtuzumab (Lemtrada®) is a humanized anti-CD52 IgG1 monoclonal antibody that depletes CD52-expressing cells from the circulation. Robust clinical and radiologic data, derived from clinical trials and long-te...

    Paolo Gallo, Diego Centonze and Maria Giovanna Marrosu

    Multiple Sclerosis and Demyelinating Disorders 2017 2:7

    Published on: 29 May 2017

  6. Review

    Pediatric versus adult MS: similar or different?

    In this review the most important aspects of pediatric multiple sclerosis are presented and compared with the adult form. Some findings appear peculiar of pediatric MS:


    Angelo Ghezzi, Damiano Baroncini, Mauro Zaffaroni and Giancarlo Comi

    Multiple Sclerosis and Demyelinating Disorders 2017 2:5

    Published on: 8 May 2017

  7. Case report

    Coincident onset of multiple sclerosis and Herpes simplex virus 1 encephalitis: a case report

    Along with vitamin D, smoking, body mass index and others, Epstein Barr virus, other herpesviruses and human endogenous retroviruses represent plausible environmental risk factors for multiple sclerosis. Howev...

    M. C. Buscarinu, A. Fornasiero, S. Romano, M. Ferraldeschi, R. Renié, G. Trasimeni, M. Salvetti and G. Ristori

    Multiple Sclerosis and Demyelinating Disorders 2017 2:6

    Published on: 28 April 2017

  8. Research article

    Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation

    Methylthioadenosine is a metabolite of the polyamine pathway that modulates methyltransferase activity, thereby influencing DNA and protein methylation. Since methylthioadenosine produces neuroprotection in mo...

    Beatriz Moreno, Gemma Vila, Begoña Fernandez-Diez, Raquel Vázquez, Alessandra di Penta, Oihana Errea, Nagore Escala, Andrés Miguez, Jordi Alberch and Pablo Villoslada

    Multiple Sclerosis and Demyelinating Disorders 2017 2:3

    Published on: 14 April 2017

  9. Research article

    Myelin-derived and putative molecular mimic peptides share structural properties in aqueous and membrane-like environments

    Despite intense research, the causes of various neurological diseases remain enigmatic to date. A role for viral or bacterial infection and associated molecular mimicry has frequently been suggested in the eti...

    Jussi Tuusa, Arne Raasakka, Salla Ruskamo and Petri Kursula

    Multiple Sclerosis and Demyelinating Disorders 2017 2:4

    Published on: 24 March 2017

  10. Review

    Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis

    Cognitive impairment is very frequent during multiple sclerosis (MS), involving approximately 40–70% of the patients, with a profound impact on patient’s life. It is now established that among the various cent...

    Andrea Mancini, Lorenzo Gaetani, Maria Di Gregorio, Alessandro Tozzi, Veronica Ghiglieri, Paolo Calabresi and Massimiliano Di Filippo

    Multiple Sclerosis and Demyelinating Disorders 2017 2:2

    Published on: 26 January 2017

  11. Research article

    The still under-investigated role of cognitive deficits in PML diagnosis

    Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in...

    Cristina Scarpazza, Nicola De Rossi, Lucia Moiola, Simonetta Gerevini, Mirco Cosottini, Ruggero Capra and Flavia Mattioli

    Multiple Sclerosis and Demyelinating Disorders 2017 2:1

    Published on: 9 January 2017

  12. Research article

    Cytokine profiles in pediatric multiple sclerosis

    The immunopathogenesis of pediatric multiple sclerosis (MS) is not well understood.

    Vikram Bhise, Konstantin Balashov, Marc Sturgill, Lauren Krupp and Suhayl Dhib-Jalbut

    Multiple Sclerosis and Demyelinating Disorders 2016 1:15

    Published on: 3 November 2016

  13. Research article

    Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis

    Immediately following immunoablation and hematopoietic stem cell transplantation (IA-HSCT) for MS a median decrease in brain volume of 3.2 % over 2.4 months occurs. After 2 years, rates of atrophy are comparab...

    Lisa A. S. Walker, Jason A. Berard, Marjorie Bowman, Harold L. Atkins, Hyunwoo Lee, Douglas Arnold and Mark S. Freedman

    Multiple Sclerosis and Demyelinating Disorders 2016 1:12

    Published on: 22 August 2016

  14. Review

    Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

    Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unkn...

    Lina Hassoun, Judith Eisele, Katja Thomas and Tjalf Ziemssen

    Multiple Sclerosis and Demyelinating Disorders 2016 1:10

    Published on: 2 August 2016

  15. Review

    The link of inflammation and neurodegeneration in progressive multiple sclerosis

    Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without unequivocal recovery. Understanding the mechanisms that determine entering in this stage o...

    Fernando Pérez-Cerdá, María Victoria Sánchez-Gómez and Carlos Matute

    Multiple Sclerosis and Demyelinating Disorders 2016 1:9

    Published on: 7 July 2016

  16. Case Report

    Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study

    Natalizumab is highly effective in reducing multiple sclerosis disease activity; however it carries a risk of progressive multifocal leukoencephalopathy, that represents the main reason of drug discontinuation...

    Simona Malucchi, Marco Capobianco, Alessia di Sapio, Marianna Lo Re, Paola Cavalla and Antonio Bertolotto

    Multiple Sclerosis and Demyelinating Disorders 2016 1:11

    Published on: 7 July 2016

  17. Review

    The heritage of glatiramer acetate and its use in multiple sclerosis

    Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous system. Treatment of MS involves disease-modifying therapies (DMTs) to reduce the incidence of relapses and pr...

    Giancarlo Comi, Maria Pia Amato, Antonio Bertolotto, Diego Centonze, Nicola De Stefano, Cinthia Farina, Paolo Gallo, Angelo Ghezzi, Luigi Maria Grimaldi, Gianluigi Mancardi, Maria Giovanna Marrosu, Enrico Montanari, Francesco Patti, Carlo Pozzilli, Leandro Provinciali, Marco Salvetti…

    Multiple Sclerosis and Demyelinating Disorders 2016 1:6

    Published on: 4 July 2016

  18. Research article

    Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis

    We aim to identify differentially expressed genes (DEGs) and its pathways associated with clinical activity of relapsing–remitting Multiple Sclerosis (RRMS).

    Ion Agirrezabal, Ricardo Palacios, Beatriz Moreno, Jorge Sepulcre, Alice Abernathy, Albert Saiz, Sara Llufriu, Manuel Comabella, Xavier Montalban, Antonio Martinez, David Arteta and Pablo Villoslada

    Multiple Sclerosis and Demyelinating Disorders 2016 1:7

    Published on: 7 June 2016

  19. Review

    Antibodies in acquired demyelinating disorders in children

    The discovery that several demyelinating disorders in children may be associated with autoantibodies to astrocytes, myelin, and/or synaptic proteins has opened the possibility of their use as diagnostic and pr...

    Thaís Armangue, Anusha K. Yeshokumar, Maria Sepúlveda, Francesc Graus and Albert Saiz

    Multiple Sclerosis and Demyelinating Disorders 2016 1:5

    Published on: 16 May 2016

  20. Research article

    Stroop event-related potentials as a bioelectrical correlate of frontal lobe dysfunction in multiple sclerosis

    Dysfunction of higher cognitive abilities occurs in 40–60 % of people with multiple sclerosis (MS), as detected with neuropsychological testing, with predominant involvement of executive functions and processi...

    N. Amato, M. Cursi, M. Rodegher, L. Moiola, B. Colombo, M. Falautano, F. Possa, G. Comi, V. Martinelli and L. Leocani

    Multiple Sclerosis and Demyelinating Disorders 2016 1:8

    Published on: 1 May 2016

  21. Research article

    A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study

    Fingolimod is approved by EMA as a second-line treatment for relapsing-remitting multiple sclerosis (RRMS). Experience with fingolimod in real life is still limited. Aim of our study was to report data on fing...

    D. Baroncini, M. Zaffaroni, P. O. Annovazzi, S. Baldini, A. Bianchi, G. Minonzio, G. Comi and A. Ghezzi

    Multiple Sclerosis and Demyelinating Disorders 2016 1:4

    Published on: 1 April 2016

Previous Page Page 1 of 2 Next Page